A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis
Authors:
- 9 February 2007
- journal article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 23 (3) , 585-594
Abstract
Objective: To explore the relationship between persistence with alendronate therapy and fracture rates in women with postmenopausal osteoporosis.Research design and methods: Claims data from a large US health plan database were used to examine persistence with therapy in postmenopausal women followed for 24 months. Persistence was defined as the time (in days) from the date of first fill to the run-out date of the last prescription with no lapses > 30 days after completion of the previous refill. A persistent cohort (length of persistence ≥ 182 days) and a non-persistent cohort (length of persistence < 182 days) were defined. The number of patients with a fracture claim in each cohort was determined. Cox-proportional hazards regression (HR) analysis was used to determine significant differences in fracture rates between the two cohorts.Results: 4769 patients were followed for 24 months. Patients in the persistent cohort were significantly more likely to receive a treatment (vs. prevention) dose of...Keywords
This publication has 39 references indexed in Scilit:
- Injectable bisphosphonates in the treatment of postmenopausal osteoporosisAging Clinical and Experimental Research, 2003
- THE MANAGEMENT OF OSTEOPOROSISThe Journal of Bone and Joint Surgery. British volume, 2001
- Risk of New Vertebral Fracture in the Year Following a FractureJAMA, 2001
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled TrialJAMA, 1999
- Vertebral Fractures and Mortality in Older WomenArchives of internal medicine (1960), 1999
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998
- Enhancing Patient Compliance in the ElderlyDrugs & Aging, 1998
- Trreatment With Alendronate Prevents Fractures in Women at Highest RiskArchives of internal medicine (1960), 1997
- Prevention of Nonvertebral Fractures by AlendronateJAMA, 1997
- A General Method of Compliance Assessment Using Centralized Pharmacy RecordsMedical Care, 1988